Ayal Schaffer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/584087/publications.pdf

Version: 2024-02-01

110	5,980	34	75
papers	citations	h-index	g-index
113	113	113	5947
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Differences in Suicide-Related Twitter Content According to User Influence. Crisis, 2023, 44, 292-299.	0.9	О
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	0.9	5
3	Clinical and demographic factors associated with delayed diagnosis of bipolar disorder: Data from Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study. Journal of Affective Disorders, 2022, 296, 506-513.	2.0	16
4	Use of a pointâ€ofâ€care webâ€based application to enhance adherence to the CANMAT and ISBD 2018 guidelines for the management of bipolar disorder. Bipolar Disorders, 2022, 24, 392-399.	1.1	3
5	Inflammatory markers, brain-derived neurotrophic factor, and the symptomatic course of adolescent bipolar disorder: A prospective repeated-measures study. Brain, Behavior, and Immunity, 2022, 100, 278-286.	2.0	12
6	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disorders, 2022, 24, 354-374.	1.1	23
7	Emergency department visits for self-harm in adolescents after release of the Netflix series â€~13 Reasons Why'. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1434-1442.	1.3	8
8	Cannabidiol in the Treatment of Mood Disorders. Current Treatment Options in Psychiatry, 2022, 9, 140-150.	0.7	1
9	A doubleâ€blind, randomized, placeboâ€controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disorders, 2021, 23, 66-75.	1.1	7
10	The association between Twitter content and suicide. Australian and New Zealand Journal of Psychiatry, 2021, 55, 268-276.	1.3	15
11	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Conc L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.	er na9 it	54
12	The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. Journal of Affective Disorders, 2021, 280, 140-147.	2.0	3
13	The Relationship Between Suicide-Related Twitter Events andÂSuicides in Ontario From 2015 to 2016. Crisis, 2021, 42, 40-47.	0.9	7
14	Putting away the crystal ball: A call for clinical guidelines in mood disorders to emphasize suicide prevention interventions over assessments of risk. Bipolar Disorders, 2021, 23, 630-631.	1.1	0
15	Expanding the target audience for management guidelines: Coâ€development of the patient and family guide to the CANMAT and ISBD bipolar disorder guidelines. Bipolar Disorders, 2021, 23, 528-530.	1.1	1
16	The Impact of a Harry Potter-Based Cognitive-Behavioral Therapy Skills Curriculum on Suicidality and Well-being in Middle Schoolers: A Randomized Controlled Trial. Journal of Affective Disorders, 2021, 286, 134-141.	2.0	8
17	Clinical correlates of suicidality and self-injurious behaviour among Canadian adolescents with bipolar disorder. European Child and Adolescent Psychiatry, 2021, , $1.$	2.8	6
18	Changes in Suicide Reporting Quality and Deaths in Ontario Following Publication of National Media Guidelines. Crisis, 2021, 42, 378-385.	0.9	5

#	Article	IF	Citations
19	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.1	32
20	Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. Frontiers in Psychiatry, 2021, 12, 769897.	1.3	0
21	The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of Affective Disorders, 2020, 262, 149-154.	2.0	14
22	The best defense is a good offense: Proactive approaches for suicide prevention in bipolar disorder. Bipolar Disorders, 2020, 22, 191-192.	1.1	1
23	What would cardiology do? Lessons from other medical specialties should help guide suicide prevention research. Australian and New Zealand Journal of Psychiatry, 2020, 54, 568-570.	1.3	2
24	Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology. Contemporary Clinical Trials Communications, 2020, 19, 100600.	0.5	8
25	Cognitive behavioral therapy for suicide prevention in youth admitted to hospital following an episode of self-harm: A pilot randomized controlled trial. Journal of Affective Disorders, 2020, 266, 686-694.	2.0	18
26	Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. Journal of Affective Disorders, 2020, 267, 185-190.	2.0	13
27	Preliminary Investigation of a Novel Cognitive Behavioural Therapy Curriculum on the Wellbeing of Middle Schoolers. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 66-75.	0.7	0
28	"l Can't Crack the Code― What Suicide Notes Teach Us about Experiences with Mental Illness and Mental Health Care. Canadian Journal of Psychiatry, 2019, 64, 98-106.	0.9	7
29	Suicides in Young People in Ontario Following the Release of "13 Reasons Why― Canadian Journal of Psychiatry, 2019, 64, 798-804.	0.9	18
30	Body mass index weight categories in adults who died by suicide: An observational study. Journal of Affective Disorders, 2019, 257, 454-460.	2.0	0
31	Management Commentary. , 2019, , 268-271.		1
32	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disorders, 2019, 21, 686-719.	1.1	69
33	A different kind of gut–brain connection: Can lessons learned from reduction of colon cancer deaths guide enhanced suicide prevention?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 583-584.	1.3	1
34	An Observational Study of Suicide Deaths by Self-Poisoning with Opioids in Toronto (1998-2015). Canadian Journal of Psychiatry, 2019, 64, 070674371983877.	0.9	3
35	Bridging the mental–physical divide in health care. Cmaj, 2019, 191, E722-E723.	0.9	2
36	Suicide deaths by gas inhalation in Toronto: An observational study of emerging methods of suicide. Journal of Affective Disorders, 2019, 243, 226-231.	2.0	5

3

#	Article	IF	CITATIONS
37	Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report. Bipolar Disorders, 2019, 21, 117-123.	1.1	38
38	What Are We Aiming For? Comparing Suicide by Firearm in Toronto With the Five Largest Metropolitan Areas in the United States. Crisis, 2019, 40, 365-369.	0.9	0
39	Media Guidelines for Reporting on Suicide: 2017 Update of the Canadian Psychiatric Association Policy Paper. Canadian Journal of Psychiatry, 2018, 63, 182-196.	0.9	40
40	Why bipolar <scp>II</scp> disorder does not deserve its status as the overlooked middle child. Bipolar Disorders, 2018, 20, 397-398.	1.1	1
41	Suicide deaths by intentional self-poisoning in people with cardiovascular disease. General Hospital Psychiatry, 2018, 52, 41-47.	1.2	7
42	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.1	1,079
43	Comparison of Vital Statistics Definitions of Suicide against a Coroner Reference Standard: A Population-Based Linkage Study. Canadian Journal of Psychiatry, 2018, 63, 152-160.	0.9	34
44	Report of the 2016 Mental Health Expert Panel on suicide prevention in the Canadian Armed Forces. Journal of Military, Veteran and Family Health, 2018, 4, 70-89.	0.3	8
45	The association between suicide deaths and putatively harmful and protective factors in media reports. Cmaj, 2018, 190, E900-E907.	0.9	67
46	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	1.3	18
47	Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting. Journal of Affective Disorders, 2018, 241, 103-109.	2.0	21
48	Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry, 2018, 18, 227.	1.1	8
49	An Observational Study of Suicide Death in Homeless and Precariously Housed People in Toronto. Canadian Journal of Psychiatry, 2017, 62, 501-505.	0.9	13
50	Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns. International Journal of Bipolar Disorders, 2017, 5, 16.	0.8	8
51	Did the suicide barrier work after all? Revisiting the Bloor Viaduct natural experiment and its impact on suicide rates in Toronto. BMJ Open, 2017, 7, e015299.	0.8	19
52	Antipsychotic adjunctive therapy to mood stabilizers and 1â€year rehospitalization rates in bipolar disorder: A cohort study. Bipolar Disorders, 2016, 18, 684-691.	1.1	9
53	Populationâ€based analysis of health care contacts among suicide decedents: identifying opportunities for more targeted suicide prevention strategies. World Psychiatry, 2016, 15, 135-145.	4.8	86
54	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectrums, 2016, 21, 403-418.	0.7	49

#	Article	IF	Citations
55	Suicide in males and females with cardiovascular disease and comorbid depression. Journal of Affective Disorders, 2016, 197, 88-93.	2.0	20
56	Building an evidence base for national suicide prevention strategies. Australian and New Zealand Journal of Psychiatry, 2016, 50, 175-176.	1.3	2
57	Suicide in the oldest old: an observational study and cluster analysis. International Journal of Geriatric Psychiatry, 2016, 31, 33-40.	1.3	35
58	A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1006-1020.	1.3	87
59	Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 785-802.	1.3	122
60	Last wills and testaments in a large sample of suicide notes: Implications for testamentary capacity. British Journal of Psychiatry, 2015, 206, 72-76.	1.7	14
61	International Society for Bipolar Disorders Task Force on Suicide: metaâ€analyses and metaâ€agression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disorders, 2015, 17, 1-16.	1.1	265
62	Suicide in Schizophrenia. Journal of Clinical Psychiatry, 2015, 76, e98-e103.	1.1	14
63	Association of Weekly Suicide Rates with Temperature Anomalies in Two Different Climate Types. International Journal of Environmental Research and Public Health, 2014, 11, 11627-11644.	1.2	55
64	Suicide in bipolar disorder: characteristics and subgroups. Bipolar Disorders, 2014, 16, 732-740.	1.1	28
65	Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials. Journal of Psychiatric Research, 2014, 53, 54-61.	1.5	13
66	Characterizing Suicide in Toronto: An Observational Study and Cluster Analysis. Canadian Journal of Psychiatry, 2014, 59, 26-33.	0.9	43
67	Medications Without a Patient. Crisis, 2014, 35, 283-285.	0.9	2
68	Evidence review and clinical guidance for the use of ziprasidone in Canada. Annals of General Psychiatry, 2013, 12, 1.	1.2	11
69	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.1	740
70	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.1	14
71	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.1	1
72	Obesity and the threeâ€year longitudinal course of bipolar disorder. Bipolar Disorders, 2013, 15, 284-293.	1.1	57

#	Article	IF	CITATIONS
73	Use of Mental Health Telemetry to Enhance Identification and Predictive Value of Early Changes During Augmentation Treatment of Major Depression. Journal of Clinical Psychopharmacology, 2013, 33, 775-781.	0.7	14
74	Substances Used in Completed Suicide by Overdose in Toronto: An Observational Study of Coroner's Data. Canadian Journal of Psychiatry, 2012, 57, 184-191.	0.9	36
75	Differentiating between Bipolar Disorder Types I and II: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Journal of Affective Disorders, 2012, 138, 46-53.	2.0	45
76	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Annals of Clinical Psychiatry, 2012, 24, 6-22.	0.6	68
77	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Annals of Clinical Psychiatry, 2012, 24, 23-37.	0.6	74
78	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Annals of Clinical Psychiatry, 2012, 24, 38-55.	0.6	42
79	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Annals of Clinical Psychiatry, 2012, 24, 56-68.	0.6	25
80	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Annals of Clinical Psychiatry, 2012, 24, 69-81.	0.6	70
81	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Annals of Clinical Psychiatry, 2012, 24, 82-90.	0.6	43
82	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of Clinical Psychiatry, 2012, 24, 91-109.	0.6	56
83	The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disorders, 2011, 13, 387-395.	1.1	150
84	Why antidepressant clinical trials fail: the role of expectations. Clinical Investigation, 2011, 1, 1207-1209.	0.0	0
85	A population-based analysis of distinguishers of bipolar disorder from major depressive disorder. Journal of Affective Disorders, 2010, 125, 103-110.	2.0	42
86	Anxiety As a Predictor of Treatment Outcome in Children and Adolescents with Depression. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 211-216.	0.7	20
87	Bipolar disorder among adolescents and young adults: Results from an epidemiological sample. Journal of Affective Disorders, 2010, 125, 350-354.	2.0	65
88	Factors Associated with Use of Mental Health Services for Depressed and/or Suicidal Youth Aged 15–24. Community Mental Health Journal, 2009, 45, 300-306.	1.1	30
89	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11 , 225 - 255 .	1.1	545
90	Bipolar disorder and leisure-time physical activity: Results from a national survey of Canadians. Mental Health and Physical Activity, 2009, 2, 65-70.	0.9	21

#	Article	IF	Citations
91	Differences in Prevalence and Treatment of Bipolar Disorder among Immigrants: Results from an Epidemiologic Survey. Canadian Journal of Psychiatry, 2009, 54, 734-742.	0.9	15
92	Benzodiazepine Use and Driving. Journal of Clinical Psychiatry, 2009, 70, 663-673.	1.1	93
93	Correlates of Suicidality Among Patients with Psychotic Depression. Suicide and Life-Threatening Behavior, 2008, 38, 403-414.	0.9	35
94	Comparison of Antidepressant Use Between Subjects With Bipolar Disorder and Major Depressive Disorder With or Without Comorbid Anxiety. Journal of Clinical Psychiatry, 2007, 68, 1785-1792.	1.1	13
95	Pharmacotherapy of Alcoholism in Patients with Co-morbid Psychiatric Disorders. Drugs, 2006, 66, 1229-1237.	4.9	20
96	Community Survey of Bipolar Disorder in Canada: Lifetime Prevalence and Illness Characteristics. Canadian Journal of Psychiatry, 2006, 51, 9-16.	0.9	116
97	Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorders, 2006, 96, 95-99.	2.0	100
98	Effect of antidepressant use on admissions to hospital among elderly bipolar patients. International Journal of Geriatric Psychiatry, 2006, 21, 275-280.	1.3	20
99	Use of Treatment Services and Pharmacotherapy for Bipolar Disorder in a General Population-Based Mental Health Survey. Journal of Clinical Psychiatry, 2006, 67, 386-393.	1.1	30
100	Double-Blind, Placebo-Controlled Pilot Study of Mexiletine for Acute Mania or Hypomania. Journal of Clinical Psychopharmacology, 2005, 25, 507-508.	0.7	3
101	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 2005, 7, 5-69.	1.1	321
102	Seasonality in a community sample of bipolar, unipolar and control subjects. Journal of Affective Disorders, 2005, 86, 19-25.	2.0	67
103	Depressive Symptoms and Alcohol Consumption among Nonalcoholic Depression Patients Treated with Desipramine. Canadian Journal of Psychiatry, 2004, 49, 859-862.	0.9	3
104	Influence of Season and Latitude in a Community Sample of Subjects with Bipolar Disorder. Canadian Journal of Psychiatry, 2003, 48, 277-280.	0.9	32
105	Utility scores of symptom profiles in major depression. Psychiatry Research, 2002, 110, 189-197.	1.7	18
106	Lower dopamine transporter binding potential in striatum during depression. NeuroReport, 2001, 12, 4121-4125.	0.6	242
107	Suicidal Ideation in Major Depression: Sex Differences and Impact of Comorbid Anxiety. Canadian Journal of Psychiatry, 2000, 45, 822-826.	0.9	50
108	Mexiletine in treatment-resistant bipolar disorder. Journal of Affective Disorders, 2000, 57, 249-253.	2.0	26

#	Article	IF	CITATIONS
109	Recommended Drug Treatment Strategies for the Alcoholic Patient. Drugs, 1998, 56, 571-585.	4.9	30
110	Effects of Gender and Age on Phenomenology and Management of Bipolar Disorder. , 0, , 359-440.		4